SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:0d53efb6-89c5-4683-9f53-cbd287d778fd"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:0d53efb6-89c5-4683-9f53-cbd287d778fd" > Capturing biologic ...

Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register–a validation study

Bröms, Gabriella (författare)
Karolinska Institutet,Karolinska Institute,Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Internal Medicine, Danderyds Hospital, Stockholm, Sweden,Karolinska Inst, Sweden; Danderyd Hosp, Sweden
Söderling, Jonas (författare)
Karolinska Institutet,Karolinska Institute,Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden,Karolinska Inst, Sweden
Sachs, Michael C. (författare)
Karolinska Institutet,Karolinska Institute,Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden,Karolinska Inst, Sweden
visa fler...
Halfvarson, Jonas, 1970- (författare)
Örebro universitet,Örebro University,Institutionen för medicinska vetenskaper,Department of Gastroenterology,Orebro Univ, Sweden
Myrelid, Pär (författare)
Linköpings universitet,Linköping University,Department of Surgery, Linköping University Hospital, Linköping, Sweden; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Kirurgiska kliniken US
Ludvigsson, Jonas F., 1969- (författare)
Karolinska Institutet,Karolinska Institute,Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro, Sweden,Karolinska Inst, Sweden; Orebro Univ Hosp, Sweden
Everhov, Åsa H. (författare)
Karolinska Institutet,Karolinska Institute,Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Sachs' Children and Youth Hospital, Stockholm South General Hospital, Stockholm, Sweden,Karolinska Inst, Sweden; Stockholm South Gen Hosp, Sweden
Olén, Ola (författare)
Karolinska Institutet,Karolinska Institute,Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Sachs' Children and Youth Hospital, Stockholm South General Hospital, Stockholm, Sweden; Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden,Karolinska Inst, Sweden; Stockholm South Gen Hosp, Sweden; Karolinska Inst, Sweden
Hjortswang, Henrik (creator_code:cre_t)
Björk, Jan (creator_code:cre_t)
Grip, Olof (creator_code:cre_t)
Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups
Andersson, Marie (creator_code:cre_t)
Lund University,Lunds universitet,Kliniska Vetenskaper, Helsingborg,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Clinical Sciences, Helsingborg,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
visa färre...
 (creator_code:org_t)
 
2021-02-25
2021
Engelska.
Ingår i: Scandinavian Journal of Gastroenterology. - : Informa UK Limited. - 0036-5521 .- 1502-7708. ; 56:4, s. 410-421
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: It is not known to what extent biologic treatment for IBD is captured in the Swedish Prescribed Drug Register (PDR) and the National Patient Register (NPR). Methods: A cross-sectional study from July 2005 until 2017, comparing data on biologic treatment in the PDR and the NPR with medical records. We assessed the proportion of started treatment episodes in the medical records that were found in the PDR/NPR ever, within +/− one year and within +/− three months; for any biologic drug, per specific drug (infliximab, adalimumab, golimumab, vedolizumab, ustekinumab), by calendar period (2005–2008, 2009–2012, and 2013–2017) and by study center. For adalimumab, we assessed the validity of end of treatment episodes. Results: Medical records of 1361 patients and 2323 treatment episodes with any biologic were reviewed and 80.1% (95% CI: 78.4–81.7) were ever captured in the PDR/NPR in. A time window of +/− one year or +/− three months reduced the sensitivity to 63.3% (95% CI: 61.3–65.3) and 52.6% (95% CI: 50.5–54.6), respectively. The sensitivity was high (>85%) for the prescribed injection drugs adalimumab, golimumab, and ustekinumab for all time windows and for adalimumab end of treatment, while considerably lower for the infusion drugs infliximab and vedolizumab. Conclusions: The PDR and the NPR are reliable data sources on treatment with injection biologics in patients with IBD in Sweden. Infliximab and vedolizumab are poorly captured, why PDR/NPR data should only be used after careful consideration of their limitations or complemented by other data sources, e.g., the disease-specific quality register SWIBREG.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Nyckelord

anti-TNF
biologics
Crohn’s disease
IBD
IBD unclassified
ulcerative colitis
validation
Crohn’s disease

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy